MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2016-2126

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2016

Diazoxide in Children With Obesity After Hypothalamic-Pituitary Lesions: A Randomized, Placebo-Controlled Trial.

Brauner Raja, Serreau Raphaël, Souberbielle Jean-Claude, Pouillot Monique, Grouazel Sophie, Recasens Christophe, Zerah Michel, Sainte-Rose Christian, Treluyer Jean-Marc

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

The objective was to evaluate the safety and efficacy of diazoxide (DZX) for decreasing obesity with hyperinsulinemia in patients treated for hypothalamic-pituitary lesions during childhood.

DESIGN

This was a double-blind, placebo-controlled trial in parallel groups using a centralized randomization process (PEDIAC).

SETTING

This was a single-center study.

PATIENTS: Among the 40 patients included, 35 fulfilled the study requirements.

INTERVENTIONS: Interventions included six-month treatment with DZX (4 mg/kg/d) or placebo.

MAIN OUTCOME MEASURES: The primary outcome was relative weight change at 2 months. Secondary outcomes were changes in absolute weight, plasma insulin concentrations, glucose peak after oral glucose tolerance test (OGTT), and glycosylated hemoglobin after 2 months.

RESULTS

Eighteen participants were randomized to the DZX group; three withdrew their consent or were excluded after the occurrence of diabetes mellitus at days 10, 10, and 35, respectively; and two dropped out because of protocol non-compliance at day 10. No statistically significant differences in baseline characteristics were observed among the 13 DZX patients and the 17 placebo patients. The relative weight changes at 2 months in the DZX and placebo groups were -0.9 and -0.5%, respectively (P = nonsignificant). No statistically significant differences were observed between the groups concerning the change in absolute weight or glycosylated hemoglobin after 2 months, but the plasma glucose concentrations (basal and after OGTT) were significantly greater in the patients receiving DZX treatment vs those receiving the placebo, whereas the plasma increases in insulin after OGTT were lower.

CONCLUSIONS

The 2-month treatment with DZX was not associated with a significant change in weight compared with placebo; however, it was associated with the occurrence of diabetes mellitus in three of 18 patients.

Для цитирования: Brauner Raja, Serreau Raphaël, Souberbielle Jean-Claude, Pouillot Monique, Grouazel Sophie, Recasens Christophe, Zerah Michel, Sainte-Rose Christian, Treluyer Jean-Marc. Diazoxide in Children With Obesity After Hypothalamic-Pituitary Lesions: A Randomized, Placebo-Controlled Trial.. The Journal of clinical endocrinology and metabolism. 2016. DOI: 10.1210/jc.2016-2126.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.